Tiazac 24-Hour Extended-Release Beads Capsules

Pronunciation: dil-TYE-a-zem
Generic Name: Diltiazem
Brand Name: Examples include Taztia XT and Tiazac

Tiazac 24-Hour Extended-Release Beads Capsules are used for:

Treating high blood pressure and chronic stable angina (chest pain). It may be used alone or in combination with other medicines. It may also be used for other conditions as determined by your doctor.

Tiazac 24-Hour Extended-Release Beads Capsules are a calcium channel blocker. It works by relaxing (dilating) your blood vessels, lowering blood pressure, and decreasing heart rate, which lowers the workload of the heart. It also dilates coronary arteries, which increases blood flow to the heart.

Do NOT use Tiazac 24-Hour Extended-Release Beads Capsules if:

• you are allergic to any ingredient in Tiazac 24-Hour Extended-Release Beads Capsules


• you have certain heart problems (eg, sick sinus syndrome, second- or third-degree heart block) and do not have a pacemaker, you have very low blood pressure, or you have fluid buildup in the lungs during or soon after a heart attack


• you are taking erythromycin

Contact your doctor or health care provider right away if any of these apply to you.

Before using Tiazac 24-Hour Extended-Release Beads Capsules:

Some medical conditions may interact with Tiazac 24-Hour Extended-Release Beads Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have heart failure, a recent heart attack with lung congestion, heart block, a very slow heart rate, or other heart problems; low blood pressure; certain stomach or intestine problems (eg, narrowing); liver disease; or kidney problems


• if you are taking other medicines for high blood pressure or heart conditions

Some MEDICINES MAY INTERACT with Tiazac 24-Hour Extended-Release Beads Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Antiarrhythmics (eg, amiodarone, dronedarone), cimetidine, clonidine, HIV protease inhibitors (eg, atazanavir, indinavir), or tricyclic antidepressants (eg, amitriptyline), because they may increase the risk of Tiazac 24-Hour Extended-Release Beads Capsules's side effects, such as heart rhythm problems


• Moricizine or rifamycins (eg, rifampin) because they may decrease Tiazac 24-Hour Extended-Release Beads Capsules's effectiveness


• Benzodiazepines (eg, alprazolam), beta-blockers (eg, propranolol), buspirone, carbamazepine, cilostazol, cisapride, colchicine, corticosteroids (eg, hydrocortisone), cyclosporine, digoxin, everolimus, fentanyl, HMG-CoA reductase inhibitors (eg, simvastatin), hydantoins (eg, phenytoin), lurasidone, macrolide antibiotics (eg, erythromycin), macrolide immunosuppressants (eg, tacrolimus), nifedipine, quinidine, ranolazine, theophylline, or vasopressin antagonists (eg, tolvaptan) because the risk of their side effects, some potentially life-threatening, may be increased by Tiazac 24-Hour Extended-Release Beads Capsules

This may not be a complete list of all interactions that may occur. Ask your health care provider if Tiazac 24-Hour Extended-Release Beads Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Tiazac 24-Hour Extended-Release Beads Capsules:

Use Tiazac 24-Hour Extended-Release Beads Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Tiazac 24-Hour Extended-Release Beads Capsules by mouth with or without food.


• Swallow Tiazac 24-Hour Extended-Release Beads Capsules whole. Do not break, crush, or chew before swallowing.


• If you cannot swallow the capsule whole, you may open it and sprinkle the contents over a spoonful of applesauce. Do not divide your dose over more than 1 spoonful. The applesauce should not be hot and should be soft enough to be swallowed without chewing. Swallow the mixture right away, followed by a glass of water. Do not crush or chew the medicine before swallowing. Do not store the mixture for future use.


• Taking Tiazac 24-Hour Extended-Release Beads Capsules at the same time each day will help you remember to take it.


• Continue to take Tiazac 24-Hour Extended-Release Beads Capsules even if you feel well. Do not miss any doses.


• If you miss a dose of Tiazac 24-Hour Extended-Release Beads Capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Tiazac 24-Hour Extended-Release Beads Capsules.

Important safety information:

• Tiazac 24-Hour Extended-Release Beads Capsules may cause dizziness, lightheadedness, or drowsiness. These effects may be worse if you take it with alcohol or certain medicines. Use Tiazac 24-Hour Extended-Release Beads Capsules with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Tiazac 24-Hour Extended-Release Beads Capsules may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.


• Tiazac 24-Hour Extended-Release Beads Capsules may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Tiazac 24-Hour Extended-Release Beads Capsules. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.


• Patients who take medicine for high blood pressure often feel tired or run down for a few weeks after starting treatment. Be sure to take your medicine even if you may not feel "normal." Tell your doctor if you develop any new symptoms.


• Do not suddenly stop taking Tiazac 24-Hour Extended-Release Beads Capsules. Your condition may get worse if you suddenly stop taking it. If you need to stop Tiazac 24-Hour Extended-Release Beads Capsules or add a new medicine, your doctor will gradually lower your dose.


• Tell your doctor or dentist that you take Tiazac 24-Hour Extended-Release Beads Capsules before you receive any medical or dental care, emergency care, or surgery.


• Be sure to have your blood pressure checked regularly while taking Tiazac 24-Hour Extended-Release Beads Capsules.


• Lab tests, including blood pressure, electrocardiogram (ECG), and heart rate, may be performed while you use Tiazac 24-Hour Extended-Release Beads Capsules. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Tiazac 24-Hour Extended-Release Beads Capsules with caution in the ELDERLY; they may be more sensitive to its effects, especially swelling of the ankles, feet, or hands; dizziness; and slow heartbeat.


• Tiazac 24-Hour Extended-Release Beads Capsules should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of taking Tiazac 24-Hour Extended-Release Beads Capsules while you are pregnant. Tiazac 24-Hour Extended-Release Beads Capsules are found in breast milk. Do not breast-feed while taking Tiazac 24-Hour Extended-Release Beads Capsules.

Possible side effects of Tiazac 24-Hour Extended-Release Beads Capsules:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; dizziness; facial flushing; headache; lightheadedness; tiredness; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); chest pain; fainting; fast, slow, or irregular heartbeat; fever, chills, or sore throat; hallucinations; mood or mental changes; personality changes; reddened, blistered, or swollen skin; severe or persistent dizziness, lightheadedness, nausea, or vomiting; shortness or breath; sudden weight gain; swelling of the feet, ankles, or hands; symptoms of liver problems (eg, dark urine, pale stools, yellowing of the skin or eyes); tender, bleeding, or swollen gums; unusual bleeding or bruising; unusual or persistent tiredness or weakness; vision changes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Tiazac side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include confusion; difficulty breathing, especially when lying down; dizziness; drowsiness; fainting; lightheadedness, especially when standing; loss of consciousness; nausea; nervousness; slurred speech; unusual weakness; very slow heart rate.

Proper storage of Tiazac 24-Hour Extended-Release Beads Capsules:

Store Tiazac 24-Hour Extended-Release Beads Capsules at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tiazac 24-Hour Extended-Release Beads Capsules out of the reach of children and away from pets.

General information:

• If you have any questions about Tiazac 24-Hour Extended-Release Beads Capsules, please talk with your doctor, pharmacist, or other health care provider.


• Tiazac 24-Hour Extended-Release Beads Capsules are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Tiazac 24-Hour Extended-Release Beads Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Tiazac resources

• Tiazac Side Effects (in more detail)
• Tiazac Use in Pregnancy & Breastfeeding
• Drug Images
• Tiazac Drug Interactions
• Tiazac Support Group
• 1 Review for Tiazac - Add your own review/rating

Compare Tiazac with other medications

• Angina Pectoris Prophylaxis
• Atrial Fibrillation
• Atrial Flutter
• Heart Failure
• High Blood Pressure
• Raynaud's Syndrome
• Supraventricular Tachycardia

Helix BioPharma Corp

Address Helix BioPharma Corp, 305 Industrial Parkway South, Unit 3, Aurora, ON L4G 6X7 Contact Details Phone: (905) 841-2300 ext. 286 Website: http://www.helixbiopharma.com/ Careers: http://www.helixbiopharma.com/careers

Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets

Pronunciation: ah-seet-ah-MIN-oh-fen/dex-brome-fen-IR-a-meen/soo-doe-e-FED-rin
Generic Name: Acetaminophen/Dexbrompheniramine/Pseudoephedrine
Brand Name: Drixoral Cold/Flu

Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets are used for:

Relieving symptoms of colds, hay fever, and allergies such as headache, sinus pain, nasal and sinus congestion, sneezing, watery eyes, runny nose, fever, and itching of the nose or throat. It may also be used for other conditions as determined by your doctor.

Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets are an analgesic, antihistamine, and decongestant combination. The analgesic works in the brain to help decrease pain. The antihistamine works by blocking histamine, a substance in the body that causes sneezing, runny nose, and watery eyes. The decongestant works by constricting blood vessels and reducing swelling in the nasal passages.

Do NOT use Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets if:

• you are allergic to any ingredient in Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets


• you are taking sodium oxybate (GHB) or you have taken furazolidone a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days


• you have severe high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems


• you are unable to urinate or are having an asthma attack

Contact your doctor or health care provider right away if any of these apply to you.

Before using Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets:

Some medical conditions may interact with Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a fast, slow, or irregular heartbeat


• if you have a history of asthma; lung problems (eg, emphysema); heart problems; diabetes; difficulty urinating; an enlarged prostate or other prostate problems; glaucoma; high blood pressure; an overactive thyroid; liver problems (eg, hepatitis) or severe kidney problems; adrenal gland problems (eg, pheochromocytoma); sleep apnea; trouble sleeping; stomach problems; ulcers; seizures; blood vessel problems; stroke; or a blockage of your stomach, intestines, or bladder


• if you drink more than 3 alcohol-containing drinks per day

Some MEDICINES MAY INTERACT with Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Beta-blockers (eg, propranolol), catechol-O-methyltransferase (COMT) inhibitors (eg, entacapone), furazolidone, indomethacin, isoniazid, sodium oxybate (GHB), or tricyclic antidepressants (eg, amitriptyline) because the side effects of Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets may be increased


• Anticoagulants (eg, warfarin), bromocriptine, digoxin, droxidopa, or hydantoins (eg, phenytoin) because the risk of side effects may be increased by Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets


• Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because the effectiveness of these medicines may be decreased

This may not be a complete list of all interactions that may occur. Ask your health care provider if Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets:

Use Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets may be taken with food if it upsets your stomach.


• Swallow Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets whole. Do not break, crush, or chew before swallowing.


• If you miss a dose of Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets.

Important safety information:

• Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets may cause drowsiness or dizziness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets. Using Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.


• Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets will add to the effects of alcohol and other depressants. Ask your pharmacist if you have questions about which medicines are depressants.


• Do not exceed the recommended dose of Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets. Doing so will not improve your condition faster and may increase your risk for side effects.


• If your symptoms do not improve within a few days or if they become worse, check with your doctor.


• Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets contains acetaminophen, dexbrompheniramine, and pseudoephedrine. Before you begin taking any new prescription or nonprescription medicine, read the ingredients to see if it also contains acetaminophen, dexbrompheniramine, or pseudoephedrine. If it does or if you are uncertain, contact your doctor or pharmacist.


• Do not take diet or appetite control medicines while you are taking Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets without checking with your doctor.


• If you consume 3 or more alcohol-containing drinks every day, ask your doctor whether you should take Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets or other pain relievers/fever reducers. Acetaminophen may cause liver damage. Alcohol use combined with Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets may increase your risk for liver damage.


• If you are scheduled for allergy skin testing, do not take Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets for several days before the test because it may decrease your response to the skin tests.


• If you have trouble sleeping, ask your doctor or pharmacist about the best time of the day to take Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets.


• Use Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets with caution in the ELDERLY because they may be more sensitive to its effects.


• Use Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets with extreme caution in CHILDREN younger than 12 years of age. Safety and effectiveness in this age group have not been confirmed.


• PREGNANCY and BREAST-FEEDING: It is unknown if Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets can cause harm to the fetus. If you become pregnant while taking Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets, discuss with your doctor the benefits and risks of using Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets during pregnancy. Some of the ingredients in Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets are excreted in breast milk. If you are or will be breast-feeding while you are using Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets, check with your doctor or pharmacist to discuss the risks to your baby.

Possible side effects of Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Dizziness; drowsiness; dry mouth, nose, or throat; headache; nausea; nervousness; trouble sleeping.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; dark urine or pale stools; difficulty urinating; excessive sweating; frequent urination; hallucinations; pounding in the chest; rapid pulse; severe nervousness; stomach pain; tremors; unusual fatigue; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Acetaminophen/Dexbrompheniramine/Pseudoephedrine side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include fast or irregular heartbeat; fever; hallucinations; nausea; seizures; sweating; tremors; trouble breathing; unusual drowsiness or dizziness; vomiting.

Proper storage of Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets:

Store Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets at 77 degrees F (25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets out of the reach of children and away from pets.

General information:

• If you have any questions about Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets, please talk with your doctor, pharmacist, or other health care provider.


• Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Acetaminophen/Dexbrompheniramine/Pseudoephedrine Controlled-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Acetaminophen/Dexbrompheniramine/Pseudoephedrine resources

• Acetaminophen/Dexbrompheniramine/Pseudoephedrine Side Effects (in more detail)
• Acetaminophen/Dexbrompheniramine/Pseudoephedrine Use in Pregnancy & Breastfeeding
• Acetaminophen/Dexbrompheniramine/Pseudoephedrine Drug Interactions
• Acetaminophen/Dexbrompheniramine/Pseudoephedrine Support Group
• 3 Reviews for Acetaminophen/Dexbrompheniramine/Pseudoephedrine - Add your own review/rating

Compare Acetaminophen/Dexbrompheniramine/Pseudoephedrine with other medications

• Cold Symptoms
• Hay Fever
• Sinus Symptoms

Aurodex

Generic Name: antipyrine and benzocaine (Otic route)

an-tee-PYE-reen, BEN-zoe-kane

Commonly used brand name(s)

In the U.S.

• A/B Otic


• Aurodex


• Auroto


• Benzotic


• Dec-Agesic A.B.


• Dolotic

Available Dosage Forms:

• Solution

Therapeutic Class: Anesthetic, Local

Pharmacologic Class: NSAID

Chemical Class: Pyrazolone

Uses For Aurodex

Antipyrine and benzocaine combination is used in the ear to help relieve the pain, swelling, and congestion of some ear infections. It will not cure the infection itself. An antibiotic will be needed to treat the infection. This medicine is also used to soften earwax so that the earwax can be washed away more easily.

In the U.S., this medicine is available only with your doctor's prescription.

Before Using Aurodex

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Infants, especially infants up to 3 months of age, may be especially sensitive to the effects of the benzocaine in this combination medicine. This may increase the chance of side effects. However, this medicine is not expected to cause different side effects or problems in older children than it does in adults.

Geriatric

Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults. Although there is no specific information comparing use of antipyrine and benzocaine in the elderly with use in other age groups, this medicine is not expected to cause different side effects or problems in older people than it does in younger adults.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

The presence of other medical problems may affect the use of antipyrine and benzocaine combination. Make sure you tell your doctor if:

• Your ear is draining—The chance of unwanted effects may be increased

Proper Use of antipyrine and benzocaine

This section provides information on the proper use of a number of products that contain antipyrine and benzocaine. It may not be specific to Aurodex. Please read with care.

You may warm the ear drops to body temperature (37 °C or 98.6 °F) by holding the bottle in your hand for a few minutes before applying the drops.

To use:

• Lie down or tilt the head so that the affected ear faces up. Gently pull the earlobe up and back for adults (down and back for children) to straighten the ear canal. Drop the medicine into the ear canal. Keep the ear facing up for about 5 minutes to allow the medicine to coat the ear canal. (For young children and other patients who cannot stay still for 5 minutes, try to keep the ear facing up for at least 1 or 2 minutes.) A sterile cotton plug may be moistened with a few drops of this medicine and gently placed at the ear opening for no longer than 5 to 10 minutes to help keep the medicine from leaking out. If you have any questions about this, check with your doctor.


• To keep the medicine as germ-free as possible, do not touch the dropper to any surface (including the ear).


• Do not rinse the dropper after use. Wipe the tip of the dropper with a clean tissue and keep the container tightly closed.

If you are using this medicine to help remove earwax, the ear should be flushed with warm water after you have used this medicine for 2 or 3 days. This is usually done by your doctor. If you have been directed to flush the ear out yourself, make sure that you have learned how to do it correctly. Follow the instructions carefully.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For otic dosage form (ear drops):
  
  • Adults and children:
    
    • For ear pain caused by an infection—Use enough medicine to fill the entire ear canal every one or two hours until the pain is relieved.
    
    
    • For softening earwax before removal—Use enough medicine to fill the entire ear canal three times a day for two or three days.
    
    
  
  

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Aurodex Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. The following side effects may mean that you are having an allergic reaction to the medicine.

Stop using the medicine right away if any of them occur. Check with your doctor if any of the following effects continue or are bothersome:

• Itching, burning, redness, or oozing sores in the ear

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Aurodex side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Aurodex resources

• Aurodex Side Effects (in more detail)
• Aurodex Use in Pregnancy & Breastfeeding
• Aurodex Support Group
• 0 Reviews for Aurodex - Add your own review/rating

• Aurodex Concise Consumer Information (Cerner Multum)


• Aurodex MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Aurodex with other medications

• Ear Wax Impaction
• Otitis Media

Tyrosine kinase inhibitors

Tyrosine kinase inhibitors are drugs that inhibit enzymes called tyrosine kinase that are critical in the proliferation pathway of cells. Tyrosine kinases are found in certain receptors or inside the cells. Inhibition of tyrosine kinase stops cell growth and multiplication, making them targets in the treatment of cancers.

Tyrosine kinase inhibitors are used to treat cancers that rely on growth factors or particular receptors that have tyrosine kinase domains for activation.

Drug List:

Pulmicort Turbohaler 100

1. Name Of The Medicinal Product

Pulmicort^® Turbohaler^® 100.

2. Qualitative And Quantitative Composition

Budesonide 100 micrograms/actuation.

There are no inactive ingredients.

3. Pharmaceutical Form

Breath-actuated metered dose powder inhaler.

4. Clinical Particulars

4.1 Therapeutic Indications

Pulmicort is recommended in patients with bronchial asthma.

4.2 Posology And Method Of Administration

Pulmicort Turbohaler is for oral inhalation

When transferring patients to Turbohaler from other devices, treatment should be individualised, whether once or twice daily dosing is being used. The drug and method of delivery should be considered.

Divided doses (twice daily):

The dosage should be individualised.

The dose should always be reduced to the minimum needed to maintain good asthma control.

Adults (including elderly) and children over 12 years of age: When starting treatment, during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids, the dosage in adults should be 200 - 1600 micrograms daily, in divided doses.

In less severe cases and children over 12 years of age, 200 - 800 micrograms daily, in divided doses, may be used. During periods of severe asthma, the daily dosage can be increased to up to 1600 micrograms, in divided doses.

Children 5 - 12 years of age: 200 - 800 micrograms daily, in divided doses. During periods of severe asthma, the daily dose can be increased up to 800 micrograms.

Once daily dosage:

The dosage should be individualised.

The dose should always be reduced to the minimum needed to maintain good asthma control.

Adults (including elderly) and children over 12 years of age: 200 micrograms to 400 micrograms may be used in patients with mild to moderate asthma who have not previously received inhaled glucocorticosteroids.

Up to 800 micrograms may be used by patients with mild to moderate asthma already controlled on inhaled steroids (e.g. budesonide or beclomethasone dipropionate), administered twice daily.

Children 5 - 12 years of age: 200 micrograms to 400 micrograms may be used in children with mild to moderate asthma who have not previously received inhaled glucocorticosteroids, or who are already controlled on inhaled steroids (e.g. budesonide or beclomethasone dipropionate), administered twice daily.

The patient should be transferred to once daily dosing at the same equivalent total daily dose; the drug and method of delivery should be considered. The dose should subsequently be reduced to the minimum needed to maintain good asthma control.

Patients should be instructed to take the once daily dose in the evening. It is important that the dose is taken consistently and at a similar time each evening.

There are insufficient data to make recommendations for the transfer of patients from newer inhaled steroids to once daily Pulmicort Turbohaler.

Patients, in particular those receiving once daily treatment, should be advised that if their asthma deteriorates (e.g. increased frequency of bronchodilator use or persistent respiratory symptoms) they should double their steroid dose, by administering it twice daily, and should contact their doctor as soon as possible.

In patients where an increased therapeutic effect is desired, an increased dose of Pulmicort is recommended because of the lower risk of systemic effects as compared with a combined treatment with oral glucocorticosteroids.

Patients maintained on oral glucocorticosteroids

Pulmicort Turbohaler may permit replacement or significant reduction in dosage of oral glucocorticosteroids while maintaining asthma control. For further information on the withdrawal of oral corticosteroids, see section 4.4.

Patients should be reminded of the importance of taking prophylactic therapy regularly, even when they are asymptomatic. A short-acting inhaled bronchodilator should be made available for the relief of acute asthma symptoms.

Instructions for the correct use of Pulmicort Turbohaler

Turbohaler is inspiratory flow-driven which means that, when the patient inhales through the mouthpiece, the substance will follow the inspired air into the airways.

Note: It is important to instruct the patient:

• To carefully read the instructions for use in the patient information leaflet, which is packed with each Turbohaler

• To breathe in forcefully and deeply through the mouthpiece to ensure that an optimal dose is delivered to the lungs

• Never to breathe out through the mouthpiece

• To rinse the mouth out with water and spit it out, or to brush the teeth after inhaling the prescribed dose, to minimise the risk of oropharyngeal thrush

The patient may not taste or feel any medication when using Turbohaler due to the small amount of drug dispensed.

4.3 Contraindications

Hypersensitivity to budesonide.

4.4 Special Warnings And Precautions For Use

Special caution is necessary in patients with active or quiescent pulmonary tuberculosis, and in patients with fungal or viral infections in the airways.

Non steroid: A therapeutic effect is usually reached within 10 days. In patients with excessive mucus secretion in the bronchi, a short (about 2 weeks) additional oral corticosteroid regimen can be given initially.

Steroid-dependent patients: When transferral from oral steroids to Pulmicort Turbohaler is started, the patient should be in a relatively stable phase. A high dose of Pulmicort Turbohaler is then given in combination with the previously used oral steroid dose for about 10 days.

After that, the oral steroid dose should be gradually reduced (by for example 2.5 milligrams prednisolone or the equivalent each month) to the lowest possible level. In many cases, it is possible to completely substitute Pulmicort for the oral steroid.

During transfer from oral therapy to Pulmicort, a generally lower systemic steroid action will be experienced which may result in the appearance of allergic or arthritic symptoms such as rhinitis, eczema and muscle and joint pain. Specific treatment should be initiated for these conditions. During the withdrawal of oral steroids, patients may feel unwell in a non-specific way, even though respiratory function is maintained or improved. Patients should be encouraged to continue with Pulmicort therapy whilst withdrawing the oral steroid, unless there are clinical signs to indicate the contrary. A general insufficient glucocorticosteroid effect should be suspected if, in rare cases, symptoms such as tiredness, headache, nausea and vomiting should occur. In these cases a temporary increase in the dose of oral glucocorticosteroids is sometimes necessary.

As with other inhalation therapy, paradoxical bronchospasm may occur, with an immediate increase in wheezing after dosing. If a severe reaction occurs, treatment should be reassessed and an alternative therapy instituted if necessary.

Patients who have previously been dependent on oral steroids may, as a result of prolonged systemic steroid therapy, experience the effects of impaired adrenal function. Recovery may take a considerable amount of time after cessation of oral steroid therapy, hence oral steroid-dependent patients transferred to budesonide may remain at risk from impaired adrenal function for some considerable time. In such circumstances, HPA axis functions should be monitored regularly.

Acute exacerbations of asthma may need an increase in the dose of Pulmicort or additional treatment with a short course of oral corticosteroid and/or an antibiotic, if there is an infection. The patient should be advised to use a short-acting inhaled bronchodilator as rescue medication to relieve acute asthma symptoms.

If patients find short-acting bronchodilator treatment ineffective or they need more inhalations than usual, medical attention must be sought. In this situation consideration should be given to the need for or an increase in their regular therapy, e.g., higher doses of inhaled budesonide or the addition of a long-acting beta agonist, or for a course of oral glucocorticosteroid.

Prolonged treatment with high doses of inhaled corticosteroids, particularly higher than the recommended doses, may result in clinically significant adrenal suppression. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. These patients should be instructed to carry a steroid warning card indicating their needs. Treatment with supplementary systemic steroids or Pulmicort should not be stopped abruptly.

Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma.

It is important, therefore, that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.

It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.

Reduced liver function may affect the elimination of glucocorticosteroids. The plasma clearance following an intravenous dose of budesonide however was similar in cirrhotic patients and in healthy subjects. After oral ingestion systemic availability of budesonide was increased by compromised liver function due to decreased first pass metabolism. The clinical relevance of this to treatment with Pulmicort is unknown as no data exist for inhaled budesonide, but increases in plasma levels and hence an increased risk of systemic adverse effects could be expected.

In vivo studies have shown that oral administration of ketoconazole and itraconazole (known inhibitors of CYP3A4 activity in the liver and in the intestinal mucosa causes an increase in the systemic exposure to budesonide. Concomitant treatment with ketoconazole and itraconazole or other potent CYP3A4 inhibitors should be avoided (see section 4.5 Interactions). If this is not possible, the time interval between administration of the interacting drugs should be as long as possible. A reduction in the dose of budesonide should also be considered.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

The metabolism of budesonide is primarily mediated by CYP3A4, one of the cytochrome p450 enzymes. Inhibitors of this enzyme, e.g. ketoconazole and itraconazole, can therefore increase systemic exposure to budesonide, (see Section 4.4 Special Warnings and Special Precautions for Use and Section 5.2 Pharmacokinetic Properties). Other potent inhibitors of CYP3A4 are also likely to markedly increase plasma levels of budesonide.

4.6 Pregnancy And Lactation

Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies, glucocorticosteroids have been shown to induce malformations (see Section 5.3). This is not likely to be relevant for humans given recommended doses, but therapy with inhaled budesonide should be regularly reviewed and maintained at the lowest effective dose.

The administration of budesonide during pregnancy requires that the benefits for the mother be weighed against the risk for the foetus. Inhaled glucocorticosteroids should be considered in preference to oral glucocorticosteroids because of the lower systemic effects at the doses required to achieve similar pulmonary responses.

Budesonide is excreted in breast milk. However, at therapeutic doses of Pulmicort Turbohaler no effects on the suckling child are anticipated. Pulmicort Turbohaler can be used during breast feeding.

4.7 Effects On Ability To Drive And Use Machines

Pulmicort Turbohaler does not affect the ability to drive or to use machines.

4.8 Undesirable Effects

Clinical trials, literature reports and post-marketing experience suggest that the following adverse drug reactions may occur:

Common (>1/100, <1/10)	• Mild irritation in the throat • Candida infection in the oropharynx • Hoarseness • Coughing
Rare (>1/10 000, <1/1 000)	• Nervousness, restlessness, depression, behavioural disturbances • Immediate and delayed hypersensitivity reactions including rash, contact dermatitis, urticaria, angioedema, bronchospasm and anaphylactic reaction. • Skin bruising

The candida infection in the oropharynx is due to drug deposition. Advising the patient to rinse the mouth out with water after each dosing will minimise the risk.

As with other inhalation therapy, paradoxical bronchospasm may occur in very rare cases (see Section 4.4).

Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. The effect is probably dependent on dose, exposure time, concomitant and previous steroid exposure, and individual sensitivity.

4.9 Overdose

The only harmful effect that follows inhalation of large amounts of the drug over a short period is suppression of hypothalamic-pituitary-adrenal (HPA) function. No special emergency action needs to be taken. Treatment with Pulmicort Turbohaler should be continued at the recommended dose to control the asthma.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

Budesonide is a glucocorticosteroid which possesses a high local anti-inflammatory action, with a lower incidence and severity of adverse effects than those seen with oral corticosteroids.

Pharmacotherapeutic group: Other drugs for obstructive airway diseases, inhalants, glucocorticoids. ATC Code: RO3B A02.

Topical anti-inflammatory effect

The exact mechanism of action of glucocorticosteroids in the treatment of asthma is not fully understood. Anti-inflammatory actions, such as inhibition of inflammatory mediator release and inhibition of cytokine-mediated immune response are probably important.

A clinical study in asthmatics comparing inhaled and oral budesonide at doses calculated to achieve similar systemic bioavailability demonstrated statistically significant evidence of efficacy with inhaled but not oral budesonide compared with placebo. Thus, the therapeutic effect of conventional doses of inhaled budesonide may be largely explained by its direct action on the respiratory tract.

In a provocation study pre-treatment with budesonide for four weeks has shown decreased bronchial constriction in immediate as well as late asthmatic reactions.

Onset of effect

After a single dose of orally inhaled budesonide, delivered via dry powder inhaler, improvement of the lung function is achieved within a few hours. After therapeutic use of orally inhaled budesonide delivered via dry powder inhaler, improvement in lung function has been shown to occur within 2 days of initiation of treatment, although maximum benefit may not be achieved for up to 4 weeks.

Airway reactivity

Budesonide has also been shown to decrease airway reactivity to histamine and methacholine in hyper-reactive patients.

Exercise-induced asthma

Therapy with inhaled budesonide has effectively been used for prevention of exercise-induced asthma.

Growth

Limited data from long term studies suggest that most children and adolescents treated with inhaled budesonide ultimately achieve their adult target height. However, an initial small but transient reduction in growth (approximately 1 cm) has been observed. This generally occurs within the first year of treatment (see section 4.4).

HPA axis function

Studies in healthy volunteers with Pulmicort Turbohaler have shown dose-related effects on plasma and urinary cortisol. At recommended doses, Pulmicort Turbohaler, causes less effect on the adrenal function than prednisolone 10mg, as shown by ACTH tests.

5.2 Pharmacokinetic Properties

After inhalation via Turbohaler, about 25 - 30% of the metered dose is deposited in the lungs.

Of the fraction which is swallowed, approximately 90% is inactivated by first pass metabolism in the liver.

The maximal plasma concentration after inhalation of 1 milligram budesonide is about 3.5 nmol/L and is reached after about 20 minutes.

Budesonide undergoes an extensive degree (approximately 90%) of biotransformation in the liver, to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6β-hydroxybudesonide and 16α-hydroxyprednisolone, is less than 1% of that of budesonide. The metabolism of budesonide is primarily mediated by CYP3A4, one of the cytochrome p450 enzymes.

In a study, 100 mg ketoconazole taken twice daily, increased plasma levels of concomitantly administered oral budesonide (single dose of 10 mg) on average, by 7.8-fold. Information about this interaction is lacking for inhaled budesonide, but marked increases in plasma levels could be expected.

5.3 Preclinical Safety Data

The acute toxicity of budesonide is low and of the same order of magnitude and type as that of the reference glucocorticosteroids studied (beclomethasone dipropionate, fluocinolone acetonide).

Results from subacute and chronic toxicity studies show that the systemic effects of budesonide are less severe than, or similar to, those observed after administration of the other glucocorticosteroids, e.g. decreased body-weight gain and atrophy of lymphoid tissues and adrenal cortex.

An increased incidence of brain gliomas in male rats, in a carcinogenicity study, could not be verified in a repeat study in which the incidence of gliomas did not differ between any of the groups on active treatment (budesonide, prednisolone, triamcinolone acetonide) and the control groups.

Liver changes (primary hepatocellular neoplasms) found in male rats in the original carcinogenicity study were noted again in the repeat study with budesonide, as well as with the reference glucocorticosteroids. These effects are most probably related to a receptor effect and thus represent a class effect.

Available clinical experience shows no indication that budesonide, or other glucocorticosteroids, induce brain gliomas or primary hepatocellular neoplasms in man.

In animal reproduction studies, corticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not appear to be relevant in humans at the recommended doses.

Animal studies have also identified an involvement of excess prenatal glucocorticosteroids, in increased risk for intrauterine growth retardation, adult cardiovascular disease and permanent changes in glucocorticoid receptor density, neurotransmitter turnover and behaviour at exposures below the teratogenic dose range.

6. Pharmaceutical Particulars

6.1 List Of Excipients

Pulmicort Turbohaler contains only active drug, budesonide. There are no propellants, lubricants, preservatives, carrier substances or other additives.

6.2 Incompatibilities

None known.

6.3 Shelf Life

24 months.

6.4 Special Precautions For Storage

Do not store above 30°C.

6.5 Nature And Contents Of Container

Polyethylene container consisting of a cover screwed onto a bottom plate. Inside this is the inhaler with its main parts: a mouthpiece, a dosing mechanism and a substance store.

The device also contains a desiccant.

100 micrograms/actuation. 200 actuations.

6.6 Special Precautions For Disposal And Other Handling

See section 4.2

7. Marketing Authorisation Holder

AstraZeneca UK Ltd

600 Capability Green,

Luton, LU1 3LU, UK.

8. Marketing Authorisation Number(S)

PL 17901/0162

9. Date Of First Authorisation/Renewal Of The Authorisation

18^th June 2002

10. Date Of Revision Of The Text

13^th August 2009

neostigmine

nee-oh-STIG-meen

Commonly used brand name(s)

In the U.S.

• Prostigmin Bromide

Available Dosage Forms:

• Tablet

Therapeutic Class: Central Nervous System Agent

Pharmacologic Class: Cholinesterase Inhibitor

Uses For neostigmine

Neostigmine is used to treat a muscle disease called myasthenia gravis. .

neostigmine is available only with your doctor's prescription .

Before Using neostigmine

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For neostigmine , the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to neostigmine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of neostigmine in the pediatric population. Safety and efficacy have not been established .

Geriatric

No information is available on the relationship of age to the effects of neostigmine in geriatric patients .

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	C	Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking neostigmine , it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using neostigmine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Succinylcholine

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of neostigmine . Make sure you tell your doctor if you have any other medical problems, especially:

• Intestine blockage (blocked gut or abdomen) or


• Kidney blockage (blocked urine flow) or


• Peritonitis (lining of the abdomen is inflamed)—Should not be used in patients with these conditions.

• Asthma or


• Bradycardia (slow heartbeat) or


• Heart attack, recent or


• Heart rhythm problems or


• Overactive thyroid or


• Seizures or


• Stomach ulcer—Use with caution. May make these conditions worse.

Proper Use of neostigmine

It is important to keep a daily record of when you take each dose and how long it lasts. This will help your doctor decide if your dose needs to be adjusted .

Dosing

The dose of neostigmine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of neostigmine . If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For oral dosage form (tablets):
  
  • For myasthenia gravis:
    
    • Adults—The usual dose is 15 to 375 milligrams (mg) each day, given in divided doses. Your doctor may adjust your dose if needed.
    
    
    • Children—Use and dose must be determined by your doctor .
    
    
  
  

Missed Dose

If you miss a dose of neostigmine , take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions While Using neostigmine

It is very important that your doctor check your progress at regular visits to make sure that neostigmine is working properly and to check for unwanted effects .

If your symptoms do not improve or if they become worse, check with your doctor .

neostigmine Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

More common

• Twitches of the muscle visible under the skin

Incidence not known

• Blurred or loss of vision


• changes in patterns and rhythms of speech


• chest pain or discomfort


• confusion


• cough


• difficult or labored breathing


• difficulty in moving


• difficulty swallowing


• disturbed color perception


• dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly


• double vision


• fast, pounding, or irregular heartbeat or pulse


• halos around lights


• hives


• irregular, fast or slow, or shallow breathing


• itching


• lightheadedness, dizziness, or fainting


• loss of consciousness


• muscle cramps and spasms


• muscle pain or stiffness


• night blindness


• no blood pressure or pulse


• noisy breathing


• overbright appearance of lights


• pain in joints


• pale or blue lips, fingernails, or skin


• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue


• seizures


• shortness of breath


• skin rash


• slow or irregular heartbeat


• slurred speech


• stopping of heart


• sweating


• tightness in chest


• trouble in speaking


• tunnel vision


• unconsciousness


• unusual tiredness or weakness


• wheezing

Get emergency help immediately if any of the following symptoms of overdose occur:

Symptoms of Overdose

• Constipation


• decreased sexual ability


• difficult urination


• dry mouth


• enlarged pupils


• muscle weakness

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Increased watering of mouth

Incidence not known

• Bloated


• constricted, pinpoint, or small pupils (black part of eye)


• diarrhea


• drowsiness


• excess air or gas in stomach or intestines


• feeling of warmth


• full feeling


• headache


• increase in mucous from lungs


• increased need to urinate


• increased sweating


• nausea


• passing gas


• passing urine more often


• redness of skin


• redness of the face, neck, arms and occasionally, upper chest


• skin rash


• stomach cramps


• vomiting

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: neostigmine side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More neostigmine resources

• Neostigmine Side Effects (in more detail)
• Neostigmine Use in Pregnancy & Breastfeeding
• Neostigmine Drug Interactions
• Neostigmine Support Group
• 0 Reviews for Neostigmine - Add your own review/rating

• neostigmine Concise Consumer Information (Cerner Multum)


• Neostigmine MedFacts Consumer Leaflet (Wolters Kluwer)


• Neostigmine Professional Patient Advice (Wolters Kluwer)


• Neostigmine Bromide Monograph (AHFS DI)

Compare neostigmine with other medications

• Myasthenia Gravis